NEUROPACE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
NEUROPACE, INC. (NPCE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $4.93 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $21.67, a 124.10% increase year-over-year.
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.67, a 51.09% increase year-over-year.
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $6.40, a 10566.67% increase year-over-year.
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $11.27, a 29.07% decline from fiscal 2024.
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $15.89, a 217.80% increase from fiscal 2023.
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $5.00, a 28.47% decline from fiscal 2022.
- NEUROPACE, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $6.99, a 1356.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.93 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $11.27 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $11.59 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $11.62 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $21.67 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $15.89 10-K · filed 2025-03-04 | |||
| 2024-09-30 | $14.67 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $12.59 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $9.67 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $5.00 10-K · filed 2025-03-04 | |||
| 2023-09-30 | $5.00 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $4.07 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $6.40 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $6.99 10-K · filed 2024-03-05 | |||
| 2022-09-30 | $7.69 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $6.90 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $0.06 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $0.48 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $0.64 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $0.03 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $0.03 10-Q · filed 2021-06-03 | |||
| 2020-12-31 | $46.82 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |